case_images: PMC5316451_01
case_images: Haematoxylin and eosin (HE) stains of the sinonasal tumour (a) x4 and (b) x20 and renal tumour (c) x4 and (d) x20.
case_images: CRIPA2017-9236780.001.jpg
case_images: PMC5316451_01_CRIPA2017-9236780.001.jpg
case_images: fig1
case_images: The sinonasal tumour demonstrated tubulocystic morphology with a brush border, glycogen-rich cells, and low grade nuclei without conspicuous mitoses (Figures 1(a) and 1(b)). The renal tumour consisted of clear tumour cells with tubulopapillary morphology with hobnailing at the luminal surface with Fuhrman grade up to 3 (Figures 1(c) and 1(d)). Immunohistochemistry revealed renal tumour positivity for RCC, CD10, and EMA and negativity for CK7 and CK20 (Figures 2 and 3 and Table 1).
case_images: Immunohistochemistry (IHC) of renal and sinonasal tumours, x2. (a) Sinonasal tumour cells were negative for CD10. (b) Renal tumour cells were strongly positive for CD10. (c) Sinonasal tumour cells were negative for RCC; however, weak staining of luminal secretions was seen. (d) Renal tumour cells demonstrated strong positivity for RCC marker. (e) Sinonasal tumour cells demonstrated positivity for CK7. (f) The renal tumour was negative for CK7; however, in this image a proximal renal tubule was seen to exhibit CK7 positivity. (g) The sinonasal tumour exhibited patchy CK20 positivity. (h) The renal tumour was negative for CK20.
case_images: CRIPA2017-9236780.002.jpg
case_images: PMC5316451_01_CRIPA2017-9236780.002.jpg
case_images: fig2
case_images: Immunohistochemistry revealed renal tumour positivity for RCC, CD10, and EMA and negativity for CK7 and CK20 (Figures 2 and 3 and Table 1).
case_images: (a) Sinonasal tumour with luminal PAS-positive secretions, x20. (b) Ki67 staining demonstrates a low mitotic index, x10.
case_images: CRIPA2017-9236780.003.jpg
case_images: PMC5316451_01_CRIPA2017-9236780.003.jpg
case_images: fig3
case_images: Immunohistochemistry revealed renal tumour positivity for RCC, CD10, and EMA and negativity for CK7 and CK20 (Figures 2 and 3 and Table 1).